SNP2Chip and Array SBS: The aim is to develop the technological platform together with our partner from Ireland.
HotSolutes: an international project with contributions from 10 partners, coordinated by STAB VIDA, Portugal (Prof. Miguel Silva Santos). The goal is to find applications within the areas of Protein Stabilization and Aggregation, DNA and Protein Microarrays, Molecular Biology Enzyme Performance, Biosensor Technology, Heterologous Protein-Production Systems, and Animal Cell Line Stabilization. Asper Biotech’s task is to improve hybridization buffers for in situ extension reactions in genotyping microarrays and microarray spotting homogenity testing.
Mutp53: an international project with 15 partners (in Sweden, Germany, France, Israel, the UK, Italy, the Netherlands, Denmark, Norway, and Czech Republic), coordinated by the Karolinska Institute (Prof. Klas Wiman and Dr. Marianne Farnebo). The goal is to explore mutp53 as a new target for inventive cancer treatment and to improve cancer treatment with minimal side effects. Asper Biotech’s contribution is to develop a p53 mutation detection test (resequencing array).
Medgenet: an international project with 15 partners, coordinated by Giovanny Romeo. The objective is to expand the human expertise in clinical genetics and cancer genetics in Mediterranean Partner Countries (MPCs) through the transfer of knowledge and technology between the two rims of the Mediterranean which share a common burden of genetic diseases. Our WP partner is CING, Cyprus (Marina Kleanthous). Asper Biotech’s contribution is to develop a beta-thalassemia microarray.
AO-DNA: an international project with contributions from 4 different partners in institutes from Germany, Switzerland, the UK and the USA. Our aim is to develop 5 different ophthalmogenetic tests (CSNB, OPA, BEST, CORNEA, and ad-RP).
Health-e-Child: an international project with contributions from 7 partners (Germany, Italy, the UK, France, Switzerland, Spain, and Greece), coordinated by Siemens AG (Jörg Freund and Prof. Edwin Morley-Fletcher). The project’s focus is in individualized disease prevention, screening, early diagnosis, therapy and follow-up of pediatric heart diseases, inflammatory diseases, and brain tumours. Asper Biotech’s contribution is to develop a microarray for children’s glioblastomas.
MolDiagPaca: an international project with contributions from 18 partners (in Germany, Spain, Italy, the UK and Sweden), coordinated by Philipps-Universität Marburg. The leader of WP5 epigenetics is Jörg Hoheisel, from Deutsches Krebsforschungszentrum (DKFZ). The aim is to provide novel molecular diagnostic tools for the prevention and diagnosis of pancreatic cancer. Asper Biotech’s contribution is to develop a functional array from a set of epigenetic markers for diagnostic and prognostic purposes, which will be analyzed in detail with respect to methylation variations in promoter regions and the first exon.